Fast-track CAR T cell therapy manufacturing implementation at your site
From initiation to clinical manufacturing in just 12 months
Developed from over 25 years of cell and gene therapy (CGT) expertise, the Cell Manufacturing Enabling Package (CMEP) empowers your team to set up a validated CAR T cell manufacturing process at your site. It equips your team with the training, tools, and guidance to move from project initiation to clinical manufacturing in just 12 to 18 months. With ready-to-use GMP document templates, aligned analytics, and hands-on support, CMEP streamlines every step of implementation.
CMEP addresses four critical areas of GMP – product, processes, procedures, and people – helping your team implement efficient and compliant CAR T cell manufacturing workflows.
12 months
from start
to clinical manufacturing
32 sites
successfully implemented
across 21 countries
25+ years
of CGT expertise
behind CMEP
What makes it possible?
CMEP is powered by eight core components, each designed to reduce complexity and accelerate your path to GMP-compliant CAR T cell therapy manufacturing.
Modular training: from setup to validation
CMEP’s 11-in-1 modular training program helps teams establish a validated, GMP-compliant CAR T cell manufacturing process step by step. Tailored to each site’s capabilities, timelines, and goals, the curriculum offers the flexibility to select individual modules or combine them as needed.
Spanning both implementation and validation phases, the program builds skills needed to operate, qualify, and maintain a robust manufacturing workflow.
Why to choose CMEP?
With CMEP, you invest in a proven, efficient path to clinical manufacturing success.
Accelerated implementation
Achieve GMP-readiness in as little as 12 months, saving 6 to 24 months compared to traditional implementation.
Built-in compliance
Our regulatory experts support you in reaching key milestones and meeting regulatory guidelines.
One-stop solution
A single trusted partner for instruments, reagents, vectors, protocols, documents, training, and support – no handoffs, everything works together by design.
The proof is in the practice
We work closely with both internal and external teams to establish GMP-compliant CAR T cell therapy manufacturing. Here’s what our expert says about developing and delivering CMEP.
The real value of CMEP lies in the time it saves. What would typically take 2 to 3 years, we help our partners achieve in just 12 to 18 months. With ready-to-use protocols, GMP document templates, and step-by-step expert support, CMEP significantly accelerates GMP readiness for cell manufacturing.
Our unique CMEP Program is essential in helping clients establish validated, GMP-compliant CAR T cell manufacturing processes that meet regulatory requirements. With decades of experience in CGT manufacturing under GMP, we confidently guide clients through the complex regulatory landscape. From the initial concept to manufacturing license application, we are committed to providing expert support at every step.
Ready to bring CAR T cell manufacturing to your site?
Contact us to learn how CMEP can help you in building a GMP-compliant workflow and accelerating access to life-saving therapies.
More resources
Scientific poster
Automated point-of-care manufacturing enables rapid translation of novel TCR T cell therapies and conventional CAR T cell therapies into the clinic
This poster highlights how automated, GMP-compliant point-of-care manufacturing enabled the rapid clinical translation of novel TCR T and CAR T therapies. These experiences directly contributed to the development of CMEP.
Webinar
Point-of-care manufacturing models: GMP aspects and regulatory pathways
This webinar provides an overview of different approaches in point-of-care manufacturing of cell and gene therapies. It discusses the current available tools and the main regulatory frameworks, as well as their possible future development.
Webinar
Empowering patient care: IPC/QC solutions for cellular therapies
Standardized in-process and quality controls (IPC/QC) are critical for reliably assessing the safety and efficacy of cellular therapies throughout cell manufacturing workflows. This webinar explores strategies for optimizing point-of-care practices, with a focus on analytical development and release testing to support regulatory compliance.
